240 related articles for article (PubMed ID: 25281755)
1. Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza.
Ramos EL; Mitcham JL; Koller TD; Bonavia A; Usner DW; Balaratnam G; Fredlund P; Swiderek KM
J Infect Dis; 2015 Apr; 211(7):1038-44. PubMed ID: 25281755
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA
Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model.
McBride JM; Lim JJ; Burgess T; Deng R; Derby MA; Maia M; Horn P; Siddiqui O; Sheinson D; Chen-Harris H; Newton EM; Fillos D; Nazzal D; Rosenberger CM; Ohlson MB; Lambkin-Williams R; Fathi H; Harris JM; Tavel JA
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807912
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study.
Hershberger E; Sloan S; Narayan K; Hay CA; Smith P; Engler F; Jeeninga R; Smits S; Trevejo J; Shriver Z; Oldach D
EBioMedicine; 2019 Feb; 40():574-582. PubMed ID: 30638863
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza.
Ali SO; Takas T; Nyborg A; Shoemaker K; Kallewaard NL; Chiong R; Dubovsky F; Mallory RM
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150460
[TBL] [Abstract][Full Text] [Related]
6. Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial.
Wang C; Cao B; Liu QQ; Zou ZQ; Liang ZA; Gu L; Dong JP; Liang LR; Li XW; Hu K; He XS; Sun YH; An Y; Yang T; Cao ZX; Guo YM; Wen XM; Wang YG; Liu YL; Jiang LD
Ann Intern Med; 2011 Aug; 155(4):217-25. PubMed ID: 21844547
[TBL] [Abstract][Full Text] [Related]
7. A Synthetic Influenza Virus Vaccine Induces a Cellular Immune Response That Correlates with Reduction in Symptomatology and Virus Shedding in a Randomized Phase Ib Live-Virus Challenge in Humans.
Pleguezuelos O; Robinson S; Fernández A; Stoloff GA; Mann A; Gilbert A; Balaratnam G; Wilkinson T; Lambkin-Williams R; Oxford J; Caparrós-Wanderley W
Clin Vaccine Immunol; 2015 Jul; 22(7):828-35. PubMed ID: 25994549
[TBL] [Abstract][Full Text] [Related]
8. Advancing treatment options for influenza: challenges with the human influenza challenge.
Fry AM; Zhong W; Gubareva LV
J Infect Dis; 2015 Apr; 211(7):1033-5. PubMed ID: 25281756
[No Abstract] [Full Text] [Related]
9. Different drug-resistant influenza A(H3N2) variants in two immunocompromised patients treated with oseltamivir during the 2011-2012 influenza season in Italy.
Piralla A; Gozalo-Margüello M; Fiorina L; Rovida F; Muzzi A; Colombo AA; Alessandrino PE; Baldanti F
J Clin Virol; 2013 Sep; 58(1):132-7. PubMed ID: 23810646
[TBL] [Abstract][Full Text] [Related]
10. Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections.
Escuret V; Cornu C; Boutitie F; Enouf V; Mosnier A; Bouscambert-Duchamp M; Gaillard S; Duval X; Blanchon T; Leport C; Gueyffier F; Van Der Werf S; Lina B
Antiviral Res; 2012 Nov; 96(2):130-7. PubMed ID: 22909899
[TBL] [Abstract][Full Text] [Related]
11. Longer virus shedding in influenza B than in influenza A among outpatients treated with oseltamivir.
Kawai N; Ikematsu H; Iwaki N; Kawashima T; Maeda T; Mitsuoka S; Kondou K; Satoh I; Miyachi K; Yamaga S; Shigematsu T; Hirotsu N; Kashiwagi S
J Infect; 2007 Sep; 55(3):267-72. PubMed ID: 17604839
[TBL] [Abstract][Full Text] [Related]
12. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.
Hayden FG; Sugaya N; Hirotsu N; Lee N; de Jong MD; Hurt AC; Ishida T; Sekino H; Yamada K; Portsmouth S; Kawaguchi K; Shishido T; Arai M; Tsuchiya K; Uehara T; Watanabe A;
N Engl J Med; 2018 Sep; 379(10):913-923. PubMed ID: 30184455
[TBL] [Abstract][Full Text] [Related]
13. Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study.
Sloan SE; Szretter KJ; Sundaresh B; Narayan KM; Smith PF; Skurnik D; Bedard S; Trevejo JM; Oldach D; Shriver Z
Antiviral Res; 2020 Dec; 184():104763. PubMed ID: 32151645
[TBL] [Abstract][Full Text] [Related]
14. Oral oseltamivir in human experimental influenza B infection.
Hayden FG; Jennings L; Robson R; Schiff G; Jackson H; Rana B; McClelland G; Ipe D; Roberts N; Ward P
Antivir Ther; 2000 Sep; 5(3):205-13. PubMed ID: 11075941
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment.
Barroso L; Treanor J; Gubareva L; Hayden FG
Antivir Ther; 2005; 10(8):901-10. PubMed ID: 16430195
[TBL] [Abstract][Full Text] [Related]
16. A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections.
Lee N; Hui DS; Zuo Z; Ngai KL; Lui GC; Wo SK; Tam WW; Chan MC; Wong BC; Wong RY; Choi KW; Sin WW; Lee EL; Tomlinson B; Hayden FG; Chan PK
Clin Infect Dis; 2013 Dec; 57(11):1511-9. PubMed ID: 24046309
[TBL] [Abstract][Full Text] [Related]
17. Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial.
Duan ZP; Jia ZH; Zhang J; Liu S; Chen Y; Liang LC; Zhang CQ; Zhang Z; Sun Y; Zhang SQ; Wang YY; Wu YL
Chin Med J (Engl); 2011 Sep; 124(18):2925-33. PubMed ID: 22040504
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies.
Rayner CR; Bulik CC; Kamal MA; Reynolds DK; Toovey S; Hammel JP; Smith PF; Bhavnani SM; Van Wart SA; Ambrose PG; Forrest A
Antimicrob Agents Chemother; 2013 Aug; 57(8):3478-87. PubMed ID: 23669386
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial.
Deng R; Lee AP; Maia M; Lim JJ; Burgess T; Horn P; Derby MA; Newton E; Tavel JA; Hanley WD
Clin Pharmacokinet; 2018 Mar; 57(3):367-377. PubMed ID: 28639229
[TBL] [Abstract][Full Text] [Related]
20. [A multicenter study of efficacy and safety of oseltamivir in treatment of naturally acquired influenza].
Li L; Cai B; Wang M; Zhu Y
Zhonghua Nei Ke Za Zhi; 2001 Dec; 40(12):838-42. PubMed ID: 16206676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
